New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
08:17 EDTISIS, BIIBIsis Pharmaceuticals data compelling, says BMO Capital
BMO Capital believes that data from a Phase I test of Isis' (ISIS) and Biogen's (BIIB) ISIS-SMN-Rx, an antisense oligonucleotide, for children with spinal muscular atrophy, suggests that the drug has a substantial clinical benefit. The firm raised its price target on Isis to $22 from $17 and maintains an Outperform rating.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTBIIBBiogen January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
05:26 EDTISISIsis receives orphan status for myotonic dystrophy drug treatment
Subscribe for More Information
January 14, 2015
07:05 EDTBIIB, ISISIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use